polyclonal rabbit anti-phosphorylated c-src  (ABclonal Biotechnology)

Journal: Molecular medicine reports

Article Title: Antitumor and anti-angiogenic activity of the recombinant human disintegrin domain of A disintegrin and metalloproteinase 15.

doi: 10.3892/mmr.2015.3636

Figure Lengend Snippet: Figure 1. rhddADAM15 reduces Src activation in Bel‑7402 cells. (A) Effects of rhddADAM15, EGF and U025 on the proliferation of Bel‑7402 cells. '+' indicates presence of reagent and '﹣' indicates absence of reagent. (B) Changes in the levels of Src and pSrc in Bel‑7402 cells following treatment with rhddADAM15. Following treatment of the Bel‑7402 cells with rhddADAM15 for 1 or 2 h, the levels of total Src, and pSrc Y416 and Y529 were detected using western blot analysis. (C) Quantification of B (*P<0.05 and **P<0.01, vs. untreated control). Data are expressed as the mean ± standard error of the mean. rhdd, recombinant human disintegrin domain; EGF, epidermal growth factor; ADAM15, A disintegrin and metalloproteinase 15; p, phosphorylated.

Article Snippet: The blots were then incubated with the following antibodies for ~2 h at 4 ̊C: Rabbit polyclonal phosphorylated Src Y416 (#2101; 1:1,000; Cell Signaling Technology, Boston, MA, USA), rabbit polyclonal phosphorylated Src Y527 (#2105; 1:1,000; Cell Signaling Technology), mouse monoclonal total Src (ab16885; 1:100; Abcam, Cambridge, UK) and mouse monoclonal β-actin (AA128; 1:1,000; Beyotime Institute of Biotechnology).

Techniques: Activation Assay, Western Blot, Control, Recombinant